Biovie is trading at $2.00, down 6.39% after closing at $2.14 on August 24, 2026; no verified announcement explains the decline.
- No verified Biovie announcement dated August 24 or August 25 explains the decline; the latest major company update remains the August 6 Parkinsonβs trial results.
- The broader market is higher pre-market, so no clear global or sector explanation is evident; confidence is low.